Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model (Q39903491)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S H Yoon

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J M Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H I Cho

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

E K Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H S Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

M Y Park

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

T G Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

19 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

489-497

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Adoptive-cell-transfer therapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Gene therapy. Safer and virus-free?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Genotoxicity of retroviral integration in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Receptor blockade with monoclonal antibodies as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Clinical trials of Herceptin(trastuzumab).

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

CD8 lethargy in the absence of CD4 help.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

A listing of human tumor antigens recognized by T cells: March 2004 update

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Efficient genetic modification of murine dendritic cells by electroporation with mRNA

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CGT.2008.98

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39903491&oldid=2203248395"